Recent years have witnessed groundbreaking progresses in the field of diabetes treatment, with a particular focus on GLP-1 receptor agonists. Among these novel therapies, retatrutide and trizepatide are emerging as https://neveplrz362111.ssnblog.com/37737134/novel-therapeutic-targets-in-diabetes-retatrutide-and-trizepatide